105 件 ・ 関連度順
概要と使いどころ
CVS Health engineering with integrated healthcare delivery across pharmacy, insurance (Aetna), and retail clinics. Triggers: 'CVS style', 'healthcare integration', 'pharmacy systems', 'Aetna', 'MinuteClinic'.
日本語の概要は準備中です。原文の説明を表示しています。
Prepare herbal remedies from Hildegard von Bingen's Physica. Covers plant identification, preparation methods (tinctures, poultices, infusions, decoctions), dosage guidance, contraindications, and safety review based on 12th-century medieval pharmacopeia. Use when needing an herbal remedy for a specific ailment using Hildegardian pharmacopeia, seeking guidance on preparation methods and dosage, researching medieval herbal medicine, or integrating Hildegard's plant wisdom into holistic health practice.
日本語の概要は準備中です。原文の説明を表示しています。
Audit pharmaceutical regulatory compliance -- inspection readiness, CAPA system effectiveness, change control pipeline, data integrity (ALCOA+), and validation lifecycle tracking..
日本語の概要は準備中です。原文の説明を表示しています。
Audit pharmaceutical QC laboratory operations -- OOS/OOT investigations, stability program trending, analytical method validation status, release testing optimization, and specification compliance..
日本語の概要は準備中です。原文の説明を表示しています。
Analyze pharmaceutical batch production records for yield optimization, process parameter tuning, deviation trending, and cycle time reduction under cGMP compliance. Triggers: phrases: "optimize batch yield", "analyze batch records", "pharma manufacturing analysis".
日本語の概要は準備中です。原文の説明を表示しています。
Drafts an Adverse Event Reporting Policy compliant with 21 CFR 312.32 (IND safety reporting), 21 CFR 314.80 (postmarketing), and ICH E2A, with multi-jurisdictional overlays (EMA, PMDA, Health Canada). Covers seriousness/causality frameworks, expedited reporting timelines, roles, documentation standards, training mandates, and QA mechanisms. Use when drafting or updating an adverse event reporting policy, pharmacovigilance policy, AE/SAE reporting SOP, or safety reporting framework for a pharmaceutical company, CRO, biotech, or clinical research institution.
日本語の概要は準備中です。原文の説明を表示しています。
Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.
日本語の概要は準備中です。原文の説明を表示しています。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/metabolism. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
日本語の概要は準備中です。原文の説明を表示しています。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/alleles. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
日本語の概要は準備中です。原文の説明を表示しています。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/clinical. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
日本語の概要は準備中です。原文の説明を表示しています。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/annotations. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
日本語の概要は準備中です。原文の説明を表示しています。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/interaction. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
日本語の概要は準備中です。原文の説明を表示しています。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
日本語の概要は準備中です。原文の説明を表示しています。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/visualization. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
日本語の概要は準備中です。原文の説明を表示しています。
METAINFORMANT rules for directory docs/pharmacogenomics. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
日本語の概要は準備中です。原文の説明を表示しています。
GPCR receptor pharmacology — agonist/antagonist/inverse-agonist/biased-agonist classification, GPCRdb structural data, receptor-ligand binding analysis, antibody-target interface (SAbDab). Use for GPCR drug discovery, biased-agonism analysis, receptor subtype selectivity questions, and orthosteric vs allosteric pocket characterization.
日本語の概要は準備中です。原文の説明を表示しています。
Drug safety and adverse event analysis — FAERS spontaneous-report mining, FDA black-box warnings, signal detection (PRR, ROR, IC), risk factors by demographic/comorbidity, and label change tracking. Use for post-market safety surveillance, AE signal investigation, drug-AE association strength scoring, and pharmacovigilance reports.
日本語の概要は準備中です。原文の説明を表示しています。
Compound-target-disease network construction and analysis for drug repurposing, polypharmacology discovery, and multi-target drug design. Uses STRING, BioGRID, ChEMBL, DGIdb, OMIM, OpenTargets. Use for off-target effect prediction, network-based drug repurposing, and identifying molecules with desired multi-target profile.
日本語の概要は準備中です。原文の説明を表示しています。
Assess drug-drug interactions — CYP metabolic interactions (substrate/inhibitor/inducer), transporter (P-gp, BCRP, OATP) effects, pharmacodynamic synergy/antagonism, clinical significance scoring, and management recommendations. Use for polypharmacy review, prescribing decision support, and safety analysis when adding or switching drugs.
日本語の概要は準備中です。原文の説明を表示しています。
Pharmacokinetic (PK) analysis of concentration-time data — non-compartmental analysis (NCA) for Cmax, Tmax, AUC (0-t and 0-∞), terminal half-life, clearance (CL), volume of distribution (Vd), MRT, and absolute bioavailability (F). Also one-compartment fitting. Use when you have plasma/serum drug concentrations over time after a dose and need PK parameters, or to compute bioavailability from IV + oral AUCs. NOT for ADMET property prediction from structure (use tooluniverse-admet-prediction).
日本語の概要は準備中です。原文の説明を表示しています。
Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.
日本語の概要は準備中です。原文の説明を表示しています。
Featurizes small molecules with Molfeat for QSAR/QSPR, chemical similarity, virtual screening, and molecular ML. Covers ECFP/MACCS fingerprints, RDKit descriptors, pharmacophores, pretrained embeddings, configuration persistence, and molecule-to-label alignment.
日本語の概要は準備中です。原文の説明を表示しています。
Access ClinPGx pharmacogenomics data (successor to PharmGKB). Query gene-drug interactions, CPIC guidelines, allele functions, for precision medicine and genotype-guided dosing decisions.
日本語の概要は準備中です。原文の説明を表示しています。
Generate professional clinical decision support (CDS) documents for pharmaceutical and clinical research settings, including patient cohort analyses (biomarker-stratified with outcomes) and treatment recommendation reports (evidence-based guidelines with decision algorithms). Supports GRADE evidence grading, statistical analysis (hazard ratios, survival curves, waterfall plots), biomarker integration, and regulatory compliance. Outputs publication-ready LaTeX/PDF format optimized for drug development, clinical research, and evidence synthesis.
日本語の概要は準備中です。原文の説明を表示しています。